Preclinical is the bucket where peptide research lives between mechanism and the clinic. Coverage on this site has tracked rodent, pig, and non-human-primate readouts for compounds that are not yet in human trials but carry the strongest claims about the next generation of peptide therapeutics.
Lead programs covered here in 2026: the Lilly + Indiana Biosciences quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) with rodent data heading to ADA 2026 May 29, the DiMarchi/Tschöp/Müller GLP-1R/GIPR/PPARα/γ/δ peptide-drug conjugate published in Nature April 30, the BMC Biotechnology DualPep-ALO cell-penetrating peptide for hair growth, the Aivocode CAQK tetrapeptide for traumatic brain injury (EMBO Mol Med, October 2025), the UTHealth BLMP6 fibulin-4 peptide for metastatic triple-negative breast cancer, and the early atherosclerotic-plaque-prevention work with GLP-1.
Stories here cover animal-model efficacy, mechanism-of-action work, and IND-enabling readouts. See #animal-models, #mechanism, and #ind for adjacent threads.
Researchers at Nanjing Medical University and Southeast University found that kidney humanin levels fell after ischemia-reperfusion injury in mice and tracked with declining kidney function and fibrosis. The analog S14G-humanin protected against fibrosis by stabilizing Suclg1, a subunit of a mitochondrial enzyme, against TRIM28-driven breakdown, and blocking Suclg1 erased the benefit, the Free Radical Biology and Medicine paper reports. The work was done in mice and has not been tested in people.
Researchers at IIT Bombay and Mumbai's Institute of Chemical Technology built an injectable hydrogel from functional amyloid peptides that kept insulin stable and released it over 90 hours in lab tests. One injection under the skin brought diabetic rats' glucose to normal within 30 minutes and held it for 60 hours before it rose again at 66 hours, far longer than free insulin. Adding sodium alginate let the team tune the release rate.
Chemists isolated xylarimides A and B, two 21-membered cyclic depsipeptides with a previously undescribed chemical unit, from the fungus Xylaria striata. Xylarimide A slowed the growth of kidney cancer cell lines and 786-O tumors in mice. It binds the autophagy protein ATG7 and suppresses AKT-mTOR signaling, driving cancer cells into lethal autophagy.
University of Occupational and Environmental Health researchers activated oxytocin-producing neurons in transgenic rats with adjuvant arthritis using a designer-receptor technique, and separately gave ordinary rats the oxytocin receptor agonist LIT-001. Both approaches reduced arthritis severity, ankle swelling, and pain-related behavior, and joints showed less inflammation and cartilage damage. The work was in male rats only.
Pharmacologists triggered chronic migraine-like sensitivity in male and female mice with repeated nitroglycerin. Liraglutide, semaglutide, and dulaglutide each reduced it in a dose-dependent way without changing weight or glucose tolerance, while propranolol raised blood sugar in males. Naloxone partly blocked semaglutide's effect, pointing to opioid signaling; the work is in mice only.
The Exos@TRM gel builds on the self-assembling RADA16 peptide, adds a TGF-β1-binding peptide and a stem cell-recruiting motif, and releases bone marrow stem cell exosomes for about a week. In rats with surgically made cartilage-and-bone defects, it cut inflammatory M1 macrophages, drew in the animals' own TGF-β1 and stem cells, and formed tissue resembling natural cartilage. The authors note the acute surgical model does not mirror chronic human cartilage wear.
The team picked EH, a β-sheet peptide that binds the immune checkpoint protein PD-L1, from an amphiphilic peptide library and grew it as aligned nanofibers inside the channels of PLGA microspheres loaded with immune-activating quantum dots. The design kept the peptide in tumors longer for sustained checkpoint blockade, and ultrasound-activated quantum dots set off immunogenic cell death. The authors report suppression of distant and metastatic tumors in animal tests.
Researchers at Hubei University of Technology, Hubei University of Medicine, and partner institutions in China reported in Microbiology Spectrum on October 28, 2026 that BmKDfsin3, a scorpion venom peptide, reduced replication of severe fever with thrombocytopenia syndrome virus (an RNA virus) and herpes simplex virus type 1 (a DNA virus) in human lung cells, mainly after the viruses entered. The peptide blocked the viruses' activation of the p38 pathway and strengthened type I and III interferon responses. It showed low toxicity to cells, red blood cells, and mice; antiviral effects have not been tested in animals or people.
Researchers at Henan University and MAXVAX Bio-tech reported in ACS Applied Bio Materials on October 28, 2026 a lipid nanoparticle with phenolic groups that holds HPV16 E6/E7 peptide antigens by hydrogen bonding, regardless of their charge, and binds manganese ions that act as an immune booster. The particles helped immune cells take up the antigens, switched on the STING pathway, and reached nearby lymph nodes after injection into muscle. In the TC-1 mouse tumor model they increased tumor-killing CD8 T cells and slowed tumor growth without visible toxicity; the work has not been tested in people.
Dental researchers at the University of Hong Kong reported in the International Endodontic Journal on October 26, 2026 that L803-mts, a peptide that inhibits the enzyme GSK-3β and so activates Wnt signaling, increased mineral formation and dentin-building markers in dental pulp stem cells under inflammatory conditions and shifted macrophages toward an anti-inflammatory state. In a rat pulp-injury model, new dentin made with L803-mts reached a mineral density similar to mineral trioxide aggregate, the standard capping material (1.17 vs 1.32 gHA/cm³), but with lower mineral volume (0.03 vs 0.06 mm³). The authors see it as a candidate for vital pulp therapy; the work has not been tested in people.
Researchers at Brazil's State University of Campinas (UNICAMP) reported in Immunology on October 25, 2026 that LW-9, a peptide isolated from the venom of the Brazilian wandering spider Phoneutria nigriventer, delayed tumor growth in mice with EO771 breast tumors, with a stronger effect combined with the chemotherapy drug doxorubicin. At 1 µg/kg it caused no significant changes in liver or kidney markers, and mice given it with doxorubicin ate more and held their weight better than mice on doxorubicin alone. Tumors in the combination group had less PD-L1 and more T cells, including GITR-positive T cells; the work is in mice.
Researchers at Peking Union Medical College Hospital and the Beijing Institute of Technology reported in Advanced Science on October 25, 2026 carrier-free nanofibers that self-assemble from a nine-amino-acid peptide that binds PD-L1 on tumor cells and a near-infrared heat-producing agent. In tumor-bearing animals, the fibers combined with near-infrared light activated the immune environment inside tumors and slowed growth with less immune-related toxicity. Because the heat treatment switched on a survival pathway in tumor cells (HSP70/AKT/mTOR), adding the mTOR inhibitor rapamycin further improved results and reduced recurrence.
Researchers at the Federal University of Mato Grosso do Sul in Brazil reported in Probiotics and Antimicrobial Proteins on October 24, 2026 that FK18, a rationally designed cationic peptide, inhibited Candida and Cryptococcus species at 5 to more than 40 µM, and at 10 µM eliminated Candida tropicalis cells within four hours. It rapidly permeabilized fungal membranes, its activity fell four-fold when extra ergosterol was added, and checkerboard tests showed strong synergy with the antifungal fluconazole. NMR showed FK18 forms a stable amphipathic helix in membrane-like environments; all results are from lab tests and simulations.
Researchers at Beihang University in Beijing reported in Genome Medicine on October 24, 2026 genetically engineered probiotic bacteria that produce GLP-1 in response to diet, compared with bacteria that release it constantly, in a mouse model of obesity. Mealtime-triggered delivery reduced fat accumulation and fatty liver more than constant delivery. Constant delivery enriched gut bacteria carrying genes for GLP-1-degrading enzymes, which the team also found in clinical samples, while diet-triggered delivery kept those bacteria low; the therapy has been tested only in mice.
Johns Hopkins University School of Medicine researchers reported in the Journal of Medicinal Chemistry on October 23, 2026 a structure-activity study of peptides derived from CKS1, identifying a proline hinge and the arrangement of water-loving and water-repelling amino acids as keys to how these peptides rupture cancer cell membranes. The lead, NF27, killed a broad range of cancer cells with little toxicity to healthy cells and low hemolysis, and the cell death it caused was immunogenic, drawing immune cells into mouse tumors. In mouse tumor models, NF27 suppressed growth and completely eradicated some tumors without observable systemic toxicity; no oncolytic peptide has been approved for clinical use.
Researchers from the Chinese Academy of Sciences' Xinjiang Institute of Ecology and Geography and the Chinese Academy of Medical Sciences reported in ACS Omega on October 23, 2026 that NA-CATH, a cathelicidin peptide first found in the Chinese cobra, was the best of five antimicrobial peptides tested on clinical multidrug-resistant Klebsiella pneumoniae and Acinetobacter baumannii in the lab, but killed all treated wax moth larvae. Screening nearly 50,000 computer-designed variants produced NA-7, which kept antibacterial activity, improved survival of Klebsiella-infected larvae compared with the parent peptide, and caused lower acute toxicity and fewer kidney changes in mice. The work is preclinical.
Researchers at Hainan Medical University reported in Molecules on October 23, 2026 a new peptide, Ed-79, found by screening the transcriptome of the sea anemone Exaiptasia diaphana: 37 amino acids held together by three disulfide bonds, made by solid-phase synthesis and folded in three oxidative steps. It killed fall armyworm (Spodoptera frugiperda) and mealworm (Tenebrio molitor) larvae in a dose-dependent way, with LD50 values of 289.5 and 367.2 pmol/g. Computer docking predicts it binds the outer vestibule of the Shaker potassium channel; that binding mode has not been confirmed experimentally.
Researchers at China Pharmaceutical University reported in Advanced Functional Materials on October 22, 2026 a leucine zipper-inspired peptide that binds the protein VHL, packed into a lipid nanocomplex carrying the T7 targeting peptide so that it reaches dopamine-producing neurons and their mitochondria. Given systemically, the complex reached those neurons within two hours, released the peptide in acidic conditions, and disrupted VHL's interaction with DVL-2, raising β-catenin and hexokinase 2 and improving mitochondrial energy production. Treatment reduced neurodegeneration and motor and coordination deficits in both an MPTP toxin model and an α-synuclein overexpression model; the work is preclinical.